News

NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST.

Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV vaccine with the potential to prevent HIV infection and treat HIV. The effectiveness of the new vaccine results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is seeking a collaboration partner for the NCI Phase 2 and 3 clinical trials for this vaccine and/or a licensing partner to bring the vaccine to market. Dr. Franchini will also discuss two other NCI technologies that further enhance the vaccine’s effectiveness:

• Improved HIV Vaccines Through Ras Activation
• Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Why Attend?
• Assess co-developing and/or licensing this technology
• Interact with the inventor, ask questions and provide feedback
• Learn how to partner with the NCI

Who should attend?
• Business development professionals
• Drug development professionals
• Biotech/pharma/academia researchers
• Investors and entrepreneurs

About the vaccine:
This new vaccine’s effectiveness in macaques results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is planning a Phase 1 clinical study on this vaccine at the NIH Clinical Center in late 2022.

What an HIV Vaccine could mean for patients – potential new standard of care:
Since 1985, the FDA approved 57 HIV therapeutics in seven HIV drug classes. The current standard of care for treating HIV infection is a daily oral treatment with antiretroviral therapeutics, which are often combined with three other HIV medications selected from at least two different HIV drug classes.

An HIV vaccine would completely change the current way HIV infections are addressed. For uninfected individuals, the HIV vaccine would protect them from contracting the disease. For infected individuals, it would substantially improve their quality of life by:
• Providing a potential cure, rather than treating symptoms
• Eliminating the virus, rather than suppressing it
• Providing a prime/boost treatment regimen for a finite amount of time, rather than lifelong daily dosing

Visit the link here for additional information and to register.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by